CCP
CYTO

Clough Capital Partners’s Altamira Therapeutics Ltd CYTO Stock Holding History

Clough Capital Partners’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-5
Closed -$1.67M – 230
2014
Q4 		$1.67M Sell
5
-1
-17% -$353K 0.06% 143
2014
Q3 		$2.97M Buy
+6
New +$2.97M 0.11% 133

Other funds holding CYTO

BAMS
Bellevue Asset Management (Switzerland) Kuesnacht, Switzerland $656M AUM 11.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Clough Capital Partners's CYTO Position: Q1 2015 in Review

Clough Capital Partners sold out of Altamira Therapeutics Ltd (CYTO) in Q1 2015, closing a stake of 5 shares — an estimated $1.67M sold.

Clough Capital Partners first reported a position in CYTO in Q3 2014 and held it in 2 quarters. The position peaked at $2.97M in Q3 2014. 7 funds tracked by Wall St. Rank hold CYTO as of Q1 2015.

  • Clough Capital Partners reported no remaining Altamira Therapeutics Ltd position as of Q1 2015 after selling out during the quarter.
  • Clough Capital Partners sold 5 Altamira Therapeutics Ltd shares in Q1 2015, an estimated $1.67M.
  • Clough Capital Partners first reported a position in Altamira Therapeutics Ltd in Q3 2014 and held it in 2 quarters.
  • Clough Capital Partners's Altamira Therapeutics Ltd position peaked at $2.97M in Q3 2014.
  • 7 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q1 2015.

Based on Clough Capital Partners's 13F filing for Q1 2015, filed 15 May 2015.